他莫昔芬在肝细胞癌中的应用。 - Suppr

Suppr

超能文献

Tamoxifen in hepatocellular carcinoma.

作者信息

Chow P, Kiat T C, Choo T B, Machin D

出版信息

Lancet. 1998 Sep 5;352(9130):819-20. doi: 10.1016/S0140-6736(05)60715-5.

DOI:10.1016/S0140-6736(05)60715-5

PMID:9737316

Abstract

摘要

相似文献

Tamoxifen in hepatocellular carcinoma.

Lancet. 1998 Sep 5;352(9130):819-20. doi: 10.1016/S0140-6736(05)60715-5.

Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.

Cancer Treat Rev. 2005 Oct;31(6):491-5. doi: 10.1016/j.ctrv.2005.07.005. Epub 2005 Oct 7.

[Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?].

Z Gastroenterol. 1998 Jul;36(7):605-7.

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.

Am J Gastroenterol. 2000 Jan;95(1):218-22. doi: 10.1111/j.1572-0241.2000.01688.x.

[Treatment of hepatocellular carcinoma with tamoxifen].

Gastroenterol Clin Biol. 1996 Mar;20(2):221-2.

Variant liver estrogen and response to tamoxifen.

Gastroenterology. 1996 Jul;111(1):271-2. doi: 10.1053/gast.1996.v111.agast961110271b.

[Tamoxifen and hepatocellular carcinoma: verdict after enthusiasm...].

Gastroenterol Clin Biol. 1996;20(6-7):609-10.

Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift.

J Gastroenterol Hepatol. 2000 Jul;15(7):725-9. doi: 10.1046/j.1440-1746.2000.02235.x.

Re: Liu et al.--Estrogen receptor status in inoperable hepatocellular carcinoma.

Am J Gastroenterol. 2001 Apr;96(4):1297-8. doi: 10.1111/j.1572-0241.2001.03720.x.

Complete regression of hepatocellular carcinoma under tamoxifen.

Am J Gastroenterol. 2000 Mar;95(3):827-9. doi: 10.1111/j.1572-0241.2000.01895.x.

引用本文的文献

Tamoxifen for adults with hepatocellular carcinoma.

Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2.

CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.

J Exp Clin Cancer Res. 2019 Jul 4;38(1):286. doi: 10.1186/s13046-019-1297-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Tamoxifen in hepatocellular carcinoma.

Lancet. 1998 Sep 5;352(9130):819-20. doi: 10.1016/S0140-6736(05)60715-5.

Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.

Cancer Treat Rev. 2005 Oct;31(6):491-5. doi: 10.1016/j.ctrv.2005.07.005. Epub 2005 Oct 7.

[Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?].

Z Gastroenterol. 1998 Jul;36(7):605-7.

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.

Am J Gastroenterol. 2000 Jan;95(1):218-22. doi: 10.1111/j.1572-0241.2000.01688.x.

[Treatment of hepatocellular carcinoma with tamoxifen].

Gastroenterol Clin Biol. 1996 Mar;20(2):221-2.

Variant liver estrogen and response to tamoxifen.

Gastroenterology. 1996 Jul;111(1):271-2. doi: 10.1053/gast.1996.v111.agast961110271b.

[Tamoxifen and hepatocellular carcinoma: verdict after enthusiasm...].

Gastroenterol Clin Biol. 1996;20(6-7):609-10.

Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift.

J Gastroenterol Hepatol. 2000 Jul;15(7):725-9. doi: 10.1046/j.1440-1746.2000.02235.x.

Re: Liu et al.--Estrogen receptor status in inoperable hepatocellular carcinoma.

Am J Gastroenterol. 2001 Apr;96(4):1297-8. doi: 10.1111/j.1572-0241.2001.03720.x.

Complete regression of hepatocellular carcinoma under tamoxifen.

Am J Gastroenterol. 2000 Mar;95(3):827-9. doi: 10.1111/j.1572-0241.2000.01895.x.

引用本文的文献

Tamoxifen for adults with hepatocellular carcinoma.

Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2.

CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis.

J Exp Clin Cancer Res. 2019 Jul 4;38(1):286. doi: 10.1186/s13046-019-1297-6.